PATENT CLAIM ANALYSIS

Application Number: 16056702
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-11
Patent Classification: ["514", "264100"]

Abstract:
The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of debrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

Claim (Index 1):
A method of providing adjuvant treatment to a patient with a prior diagnosis of melanoma which has been resected, comprising the step of administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

Metadata:
- Claim Count in Document: 15.0
- Percentile: 96.0
- Lexical Diversity: 1.20588
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11166862', '09904263', '13791841', '14893746', '14424424']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7393420412424422
- 35 USC 102 Novelty (BERT): 0.4859941220628095
- Combined Prediction Score: 0.7140072493244789
- Mean Citation Score: 173.356476
- Max Citation Score: 178.6649
- Similarity Product: 121.6310528471947

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test